Literature DB >> 15163321

Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference.

M Okuda1, Y Yamamoto.   

Abstract

Commercial activated partial thromboplastin time (APTT) reagents prepared with phospholipid extracted from animal or plant sources often differ in their response to heparin and coagulation factors and in their reference values. It is also known that there are variations in phospholipid composition and preparation procedure. The present study attempted to demonstrate that an APTT reagent based on synthetic phospholipids (phosphatidylethanolamine, phosphatidylcholine and phosphatidylserine), which are substances of high purity and homogeneity, reduces batch-to-batch difference when compared with two traditional APTT reagents derived from rabbit brain and soybean. Three types of APTT reagent (SYN-APTT, RBT-APTT, SOY-APTT), prepared respectively from synthetic phospholipid, rabbit brain, and soybean, were tested. The total batch-to-batch difference was coefficient of variation (CV) 0.7-2.4% in the five reagents prepared from synthetic phospholipid (SYN-APTT), but CV 1.5-10.3% in the two traditional reagents (RBT-APTT and SOY-APTT). Additionally, high-performance liquid chromatography (HPLC) analysis showed clear variation in the phospholipid composition of the RBT-APTT and SOY-APTT reagents. In conclusion, the SYN-APTT reagent derived from synthetic phospholipid was shown to reduce batch-to-batch difference, and we therefore suggest that synthetic phospholipid is a substance useful in the preparation of APTT reagent and could contribute to stability of supply and uniform diagnosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163321     DOI: 10.1111/j.1365-2257.2004.00605.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  7 in total

1.  A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity.

Authors:  Tomoko Matsumoto; Keiji Nogami; Midori Shima
Journal:  Int J Hematol       Date:  2016-10-11       Impact factor: 2.490

2.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

Authors:  Takehisa Kitazawa; Tomoyuki Igawa; Zenjiro Sampei; Atsushi Muto; Tetsuo Kojima; Tetsuhiro Soeda; Kazutaka Yoshihashi; Yukiko Okuyama-Nishida; Hiroyuki Saito; Hiroyuki Tsunoda; Tsukasa Suzuki; Hideki Adachi; Taro Miyazaki; Shinya Ishii; Mika Kamata-Sakurai; Takeo Iida; Aya Harada; Keiko Esaki; Miho Funaki; Chifumi Moriyama; Eriko Tanaka; Yasufumi Kikuchi; Tetsuya Wakabayashi; Manabu Wada; Masaaki Goto; Takeshi Toyoda; Atsunori Ueyama; Sachiyo Suzuki; Kenta Haraya; Tatsuhiko Tachibana; Yoshiki Kawabe; Midori Shima; Akira Yoshioka; Kunihiro Hattori
Journal:  Nat Med       Date:  2012-09-30       Impact factor: 53.440

3.  A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.

Authors:  Tomoko Matsumoto; Keiji Nogami; Kenichi Ogiwara; Midori Shima
Journal:  Int J Hematol       Date:  2009-11-25       Impact factor: 2.490

4.  Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.

Authors:  Zenjiro Sampei; Tomoyuki Igawa; Tetsuhiro Soeda; Miho Funaki; Kazutaka Yoshihashi; Takehisa Kitazawa; Atsushi Muto; Tetsuo Kojima; Satoshi Nakamura; Kunihiro Hattori
Journal:  MAbs       Date:  2015       Impact factor: 5.857

5.  Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment.

Authors:  Miriam Ana González-Cela-Casamayor; José Javier López-Cano; Irene Bravo-Osuna; Vanessa Andrés-Guerrero; Marta Vicario-de-la-Torre; Manuel Guzmán-Navarro; José Manuel Benítez-Del-Castillo; Rocío Herrero-Vanrell; Irene Teresa Molina-Martínez
Journal:  Pharmaceutics       Date:  2022-07-04       Impact factor: 6.525

6.  Comparative analysis on characteristics of two activated partial thromboplastin time reagents.

Authors:  Yutaro Yasui; Toshiaki Ishii; Junko Tatebe; Toshisuke Morita
Journal:  J Clin Lab Anal       Date:  2022-07-19       Impact factor: 3.124

7.  Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.

Authors:  Zenjiro Sampei; Tomoyuki Igawa; Tetsuhiro Soeda; Yukiko Okuyama-Nishida; Chifumi Moriyama; Tetsuya Wakabayashi; Eriko Tanaka; Atsushi Muto; Tetsuo Kojima; Takehisa Kitazawa; Kazutaka Yoshihashi; Aya Harada; Miho Funaki; Kenta Haraya; Tatsuhiko Tachibana; Sachiyo Suzuki; Keiko Esaki; Yoshiaki Nabuchi; Kunihiro Hattori
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.